Crism TherapeuticsLSE:CRTX Operating Margin % is 0.00% as of Jun. 2025. The stock has 3 warning signs investors should review. Among 942 Biotechnology companies, Crism Therapeutics ranks worse than 90.98% on this metric.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Crism Therapeutics Operating Margin % Related Terms
Crism Therapeutics Operating Margin % Historical Data
* Premium members only.
The historical data trend for Crism Therapeutics's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:CRTX vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Crism Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crism Therapeutics Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crism Therapeutics's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Crism Therapeutics's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Crism Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crism Therapeutics (LSE:CRTX) has a Operating Margin % of 0.00% as of Jun. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Crism Therapeutics and its competitors. According to the industry distribution chart, Crism Therapeutics ranks #857 out of 942 companies in the Biotechnology industry, placing it in the top 91%.
Is Crism Therapeutics' Operating Margin % too high?
Crism Therapeutics' current Operating Margin % is 0.00%. Based on the distribution chart, Crism Therapeutics ranks #857 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Crism Therapeutics' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Crism Therapeutics ranks #857 out of 942 companies for Operating Margin %. This places Crism Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Crism Therapeutics and its competitors. Crism Therapeutics's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (LSE:CRTX) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Crism Therapeutics (LSE:CRTX), the current Operating Margin % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:CRTX has been successfully added to your 